Atropos Health is integrating the American Society of Clinical Oncology® (ASCO®) Guidelines into their platform and presenting rare disease AI algorithms at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
Atropos Health announced the expansion of its oncology precision medicine capabilities by publishing new AI algorithms for progression monitoring for existing Paroxysmal Nocturnal Hemoglobinuria (PNH) patients. Designed to reduce the risk of serious sequelae in diagnosed patients, these AI tools are now available for health system use and are additional capabilities to the previously published algorithm to improve earlier diagnosis. Additionally, the company is simultaneously integrating American Society of Clinical Oncology (ASCO) guidelines into its platform to provide physicians with immediate access to evidence-based treatment recommendations.